RxDoctor Payments Data

Walaa Dabbas

Nephrology · Chicago, ILNPI 1417474669

Payments from drug & device makers

$721in general payments, 2019–2025

Across 12 payments — averaging $60.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$176
  • Travere Therapeutics, Inc.$158
  • Apellis Pharmaceuticals, Inc.$123
  • Otsuka America Pharmaceutical, Inc.$123
  • Novartis$60
  • Sanofi-aventis U.S. LLC$44
  • plus $36 from 2 others

What the payments were for

  • Food & beverage$62186%
  • Education$10014%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$721 in reported general payments places this provider in the 50th percentile of 524 nephrology providers in Illinois.

See all nephrology providers in Illinois

Medicare billing

Part B allowed, 2024
$91,044
Medicare patients
238
Services billed
667

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PrevymisLetermovir42$288,196
Atovaquone180$121,095
LokelmaSodium Zirconium Cyclosilicate99$100,146
Envarsus XrTacrolimus38$48,294
Cinacalcet Hcl75$33,996
JardianceEmpagliflozin21$28,714
Valganciclovir Hcl89$22,195
VeltassaPatiromer Calcium Sorbitex17$18,006
EliquisApixaban11$11,929
Mycophenolic AcidMycophenolate Sodium28$11,422
JanuviaSitagliptin Phosphate19$10,984
Sevelamer Carbonate24$7,637
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog28$6,028
Nifedipine ErNifedipine203$5,705
Dapsone94$5,679

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaLokelma$176$100,14699 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 524 nephrology providers in Illinois.

Other nephrology in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →